Colorectal cancer as a model for immunotherapy

Clinical Cancer Research

Volumn 5, Issue 2, 1999, Pages 225-236

  Foon, Kenneth A ^a,b   Yannelli, John ^a   Bhattacharya Chatterjee, Malaya ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MONOCLONAL ANTIBODY; RECOMBINANT VACCINE; TUMOR VACCINE;

CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RESEARCH; COLORECTAL CANCER; DRUG RESEARCH; HUMAN; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CARBOHYDRATES; COLORECTAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; MUCINS; RADIOIMMUNOTHERAPY; VACCINES, SYNTHETIC;

EID: 0033009499     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (163)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer Strategies, 1998. CA Cancer J. Clin., 48: 6-29, 1998.
2. Cohen, A. M., Minsky, B. D., and Shilsky R. L. Cancer of the colon. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer Principles and Practice of Oncology, Ed. 5, pp. 1144-1197. New York: Lippincott-Raven, 1997.
3. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., and Glick, J. H. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med, 122: 321-326, 1995.
4. Wolmark, N., Rockette, H., and Fisher B. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J. Clin. Oncol., 11: 1879-1887, 1993.
5. Haller, D. G., Catalano, P. J., Macdonald, J. S., and Mayer, R. J. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc. Am. Soc. Clin. Oncol., 17: 256a, 1998.
6. Riethmuller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, H., Buggisch, P., Witte, J., and Pichlmayr, R. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol., 16: 1788-1794, 1998.
7. Ziegler, L. D., Palazzolo, P., Cunningham, J., Janus, M., Itoh, K., Hayakawa, K., Hellström, L, Hellström, K. E., Nicaise, C., Dennin, R., and Murray, J. L. Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J. Clin. Oncol., 9: 1470-1478, 1992.
8. Saleh, M. N., Khazaeli, M. B., Wheeler, R. H., Bucy, R. P., Liu, T., Everson, M. P., Munn, D. H., Schlom, J., and LoBuglio, A. F. Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer. Cancer Res, 55: 4339-4346, 1995.
9. Ragnhammar, P., Fagerberg, J., Frödin, J. E., Hjelm, A. L., Lindemalm, C., Magnusson, I., Masucci, G., and Mellstedt, H. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma-long-lasting, complete remissions can be induced. Int. J. Cancer, 53: 751-758, 1993.
10. Sears, H. F., Atkinson, B., and Herlyn D. The use of monoclonal antibody in a phase I clinical trial of human gastrointestinal tumors. Lancet, 1: 762-765, 1982.
11. Sears, H. F., Steplewski, A., Herlyn, D., and Koprowski, H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J. Biol. Response Modif., 3: 138-150, 1983.
12. Sears, H. F., Herlyn, D., Steplewski, A., and Koprowski, H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res., 45: 5910-5913, 1985.
13. Weiner, L. M., Moldofsky, P. J., and Gatenby, R. A. Antibody delivery and effector cell activation in a Phase II trial of recombinant γ-interferon and murine monoclonal antibody CD 17-1A in advanced colorectal carcinoma. Cancer Res., 48: 2568-2573, 1988.
14. Fagerberg, J., Hjelm, A. L., Ragnhammar, P., Frödin, J. E., Wigzell, H., and Mellstedt, H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res., 55: 1824-1827, 1995.
15. Riethmüller, G., Schneider-Gädicke, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., Witte, J., and the German Cancer Aid 17-1A Study Group. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet, 343: 1177-1183, 1994.
16. Hellström, I., Horn, D., and Linsley P. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res., 46: 3917-3923, 1986.
17. Hellström, I., Beaumier, P. L., and Hellström, K. E. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc. Natl. Acad. Sci. USA, 83: 7059-7063, 1986.
18. Murara, R., Wunderhih, D., Thor, A., Cunningham, R., Mogenchi, P., and Schlom J. A monoclonal antibody (D612) with selective reactivity for malignant and normal gastrointestinal epithelium. Int. J. Cancer, 43: 598-607, 1989.
19. Pendurthi, T. K., Schlom, J., and Primus, F. J. Human lymphokineactivated killer cells augment immunotherapy of human colon carcinoma xenografts in monoclonal antibody D612. J. Immunother., 10: 2-12, 1991.
20. Qi, C., Nieroda, C., De Filippi, R., Greiner, J. W., Correale, P., Schlom, J., and Tsang, K. Y. Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells. Immunol. Lett., 47: 15-24, 1995.
21. Saleh, M. N., Khazaeli, M. B., Grizzle, E., Wheeler, R. H., Lawson, S., Liu, T., Russell, C., Meredith, R., Schlom, J., and LoBuglio, A. E. A Phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer. Cancer Res., 53: 4555-4562, 1993.
22. Abdel-Nabi, H., Doerr, R. J., Chan, H. W., Balu, D., Schmelter, R. F., and Maguire, R. In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results. Radiology, 1: 163-171, 1990.
23. Doerr, R. J., Abdel-Nabi, H., Krag, D., and Mitchell, E. Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study. Ann. Surg., 2: 118-124, 1991.
24. Winzelberg, G. G., Grossman, S. J., Rizk, S., Joyce, J. M., Hill, J. B., Atkinson, D. P., Sudina, K., Anderson, K., McElwain, D., and Jones, A. M. Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Correlation with computed tomography, surgery, histopathology, immunohistology, and human immune response. Cancer (Phila.), 7: 1656-1663, 1992.
25. 111inlabeled monoclonal antibody conjugate CYT-103. Gastrointest. Radiol., 16: 251-255, 1991.
26. Moffat, F. L., Jr., Pinsky, C. M., Hammershaimb, N. J., Petrelli, N. J., Patt, Y. Z., Whaley, F. S., and Goldenberg, D. M. for the Immunomedics Study Group. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase II trial. J. Clin. Oncol., 8: 2295-2305, 1996.
27. Welt, S., Divgi, C. R., Scott, A. M., Garin-Chesa, P., Finn, R. D., Graham, M., Carswell, E. A., Cohen, A., Larson, S. M., Old, L. J., and Rettig, W. J. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J. Clin. Oncol., 6: 1193-1203, 1994.
28. Divgi, C. R. Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer. Oncology, 10: 939-953, 1996.
29. Wilder, R. B., DeNardo, G. L., and DeNardo, S. J. Radioimmunotherapy: recent results and future directions. J. Clin. Oncol., 4: 1383-1400, 1996.
30. Goldenberg, D. M. Monoclonal antibodies in cancer detection and therapy. Am. J. Med., 94: 297-312, 1993.
31. 131I-CC49 in colorectal cancer. Cancer (Phila.), 73: 1057-1066, 1994.
32. Meredith, R. F., Bueschen, A. J., and Khazaeli, M. B. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J. Nucl. Med., 33: 23-29, 1992.
33. Welt, S., Divgi, C. R., and Kemeny, N. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol., 12: 1561-1571, 1994.
34. Welt, S., Scott, A. M., Divgi, C. R., Kemeny, N. E., Finn, R. D., Daghighian, F., St. Germain, J., Richards, E. C., Larson, S. M., and Old, L. J. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol., 6: 1787-1797, 1996.
35. Stickney, D. R., Anderson, L. D., Slater, A. J. B., Ahlem, C. N., Kirk, G. A., Schweighardt, S. A., and Frincke, J. M. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res., 51: 6650-6655, 1991.
36. Paganelli, G., Magnani, P., and Zito, F. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res, 51: 6960-6966, 1991.
37. Shaw, D. R., Khazaeli, M. B., and LoBuglio, A. F. Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. J. Natl. Cancer Inst., 80: 1553-1559, 1988.
38. Jones, P. T., Dear, P. H., and Foote J. Replacing the complementarity-determining regions in a human antibody with those from the mouse. Nature (Lond.), 321: 522-525, 1986.
39. Reichmann, L., Clark, M. R., and Waldmann, H. Reshaping antibodies for therapy. Nature (Lond.), 332: 323-327, 1988.
40. 131I-chimeric mouse/human B72.3 (human γ4) monoclonal antibody in humans. Cancer Res., 51: 5461-5466, 1991.
41. Osanto, S. Vaccine trials for the clinician: prospects for tumor antigens. Oncologist, 2: 284-299, 1997.
42. Brodsky, F. M., and Guagliardi, L. E. The cell biology of antigen processing and presentation. Annu. Rev. Immunol., 9: 707-744, 1991.
43. Parham, P. Antigen processing. Transporters of delight. Nature (Lond.), 348: 674-675, 1990.
44. Townsend, A., and Bodmer, H. Antigen recognition by class 1 restricted T lymphocytes. Annu. Rev. Immunol., 7: 601-624, 1989.
45. Monaco, J. A molecular model of MHC class-1-restricted antigen processing. Immunol. Today, 13: 173-179, 1992.
46. Falk, K., Rotzchke, O., and Stevanovic, J. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (Lond.), 351: 290-294, 1991.
47. Falk, K., and Rotzchke, O. Consensus motifs and peptide ligands of MHC class I molecules. Semin. Immunol., 5: 81-87, 1993.
48. Keene, J., and Forman, J. Helper activity is required for the in vitro generation of cytotoxic T lymphocytes. J. Exp. Med., 150: 11343-1142, 1982.
49. Raulet, D., and Bevan, M. Helper T cells for cytotoxic T lymphocytes need not be region restricted. J. Exp. Med, 755: 1766-1784, 1982.
50. Kast, W., Bronklhorst, DeWaal, L., and Melief, C. J. Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. J. Exp. Med., 164: 723-738, 1986.
51. Steinman, R. M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9: 271-296, 1991.
52. Allison, J. P., Hurwitz, A. A., and Leach, D. R. Manipulation of co-stimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol., 7: 682-686, 1995.
53. Fitch, F. W., Laneki, D. W., and Gajewski, T. F. T-cell mediated immune regulation: help and suppression. In: W. Paul and E. Nita (eds.), Fundamental Immunology, pp. 733-761. New York: Raven Press, 1993.
54. Zinkernagel, R., and Doherty, P. MHC-restricted cytotoxic cell: studies on the biological role of polymorphic major transplantation antigens determining T cell restriction-specificity, function and responsiveness. Adv. Immunol., 27: 51-106, 1979.
55. Rock, K. L., Gamble, S., and Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science (Washington DC), 249: 918-921, 1990.
56. Grant, E. P., and Rock, K. L. MHC class I-restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J. Immunol., 148: 13-18, 1992.
57. Rock, K. L., Rothstein, L., and Gamble, S. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J. Immunol., 150: 438-446, 1993.
58. Harding, C. V., and Song, R. Phagocytic processing of exogenous paniculate antigens by macrophages for presentation by class I MHC molecules. J. Immunol., 153: 4925-4933, 1994.
59. Kovacsovic-Bankowski, M., and Rock, K. L. A phagosome-tocytosol pathway for exogenous antigens presented on MHC class I molecules. Science (Washington DC), 267: 243-245, 1995.
60. Hoover, H. C., Jr., Brandhorst, J. S., Peters, L. C., Surdyke, M. G., Takeshita, Y., Madariaga, J., Muenz, L. R., and Hanna, M. G., Jr. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J. Clin. Oncol., 11: 390-399, 1993.
61. Hanna, M. G., Jr., Pollack, V. A., and Peters, L. C. Active-specific immunotherapy of established micrometastases with BCG plus tumor cell vaccines: effective treatment of BCG side effects with isoniazid. Cancer (Phila.), 49: 659-664, 1982.
62. Hoover, H. C., Jr., Peters, L. C., and Brandhorst, J. S. Therapy of spontaneous metastases with an autologous tumor vaccine in a guinea pig model. J. Surg. Res., 30: 409-415, 1981.
63. Key, M. E., and Hanna, M. G., Jr. Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity. 1. Synergism between BCG and line 10 tumor cells in the induction of an inflammatory response. J. Natl. Cancer Inst., 67: 853-861, 1981.
64. Peters, L. C., and Hanna, M. G., Jr. Active-specific immunotherapy of established micrometastasis: effect of cryopreservation procedures, on tumor cell immunogenicity in guinea pigs. J. Natl. Cancer Inst., 64: 1521-1525, 1980.
65. Peters, L. C., Brandhorst, J. S., and Hanna, M. G., Jr. Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res., 39: 1353-1360, 1979.
66. Ockert, D., Schirrmacher, V., Beck, N., Stoelben, E., Ahlert, T., Flechtenmacher, J., Hagmüller, E., Buchik, R., Nagel, M., and Saeger, H. D. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin. Cancer Res., 2: 21-28, 1996.
67. Gilboa, E., and Lyerly, H. K. Specific active immunotherapy of cancer using genetically modified tumor vaccines. Biol. Ther. Cancer, 6: 1-16, 1994.
68. Yannelli, J. R., Hyatt, C., Johnson, S., Hwu, P., and Rosenberg, S. A. Characterization of human tumor cell lines with the cDNA encoding either tumor necrosis factor-α (TNF-a) or interleukin-2 (IL-2). J. Immunol. Methods, 161: 77-90, 1993.
69. Bixby, D. L., and Yannelli, J. R. CD80 expression in an HLA-A2 positive human non-small cell lung cancer cell line enhances proliferation and cytotoxicity of -A2 positive T-cells derived from normal donors and patients with non-small cell lung cancer. Int. J. Cancer, 78: 685-694, 1998.
70. Chen, T., Linsley, P. S., and Hellström, K. E. Costimulation of T-cells for tumor immunity. Immunol. Today, 14: 483-486, 1993.
71. Chen, L., McGown, P., Ashe, S., Johnson, J., Li. Y., Hellström, I., and Hellström, K. E. Tumor immunogenicity determines the effect of B7 costimulation on T-cell mediated tumor immunity. J. Exp. Med., 179: 523-532, 1994.
72. Townsend, S. E., and Allison, J. P. Tumor rejection after direct costimulation of CDS+ T-cells by B7-transfected melanoma cells. Science (Washington DC), 259: 368-370, 1993.
73. Yang, S., Darrow, T. L., and Seigler, H. F. Generation of primary tumor specific cytotoxic lymphocytes from autologous and human lymphocyte antigen class I matched allogeneic peripheral blood lymphocytes by B7 gene modified melanoma cells. Cancer Res., 57: 1561-1568, 1997.
74. Jaffee, E., Dranoff, G., and Cohen, L. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res., 53: 2221-2226, 1993.
75. Fearon, E., Pardoll, D., and Itaya, T. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60: 397-403, 1990.
76. McLaughlin, J. P., Abrams, S., Kantor, J., Dobrzanski, M. J., Greenbaum, J., Schlom, J., and Greiner, J. W. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity. J Immunother., 20: 449-459, 1997.
77. Kawakami, Y., Eliyahu, S., and Sakaguchi, K. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
78. Kawakami, Y., Eliyahu, S., and Sakaguchi, K. Recognition of multiple epitopes in the human melanoma antigen gp100 associated with in vivo tumor regression. J. Immunol., 154: 3961-3968, 1995.
79. Bakker, A., Schreurs, M., and Tafazzul, G. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int. J. Cancer, 62: 97-102, 1995.
80. Kawakami, Y., Eliyahu, S., and Delgado, C. H. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA, 91: 6458-6462, 1994.
81. + cytotoxic T lymphocytes. J. Exp. Med., 181: 363-368, 1995.
82. Brichard, V., Van Pel, A., and Wölfel, T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T-lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178: 759-764, 1993.
83. Traversari, C., Van der Bruggen, P., and Luescher, F. A non-apeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T-lymphocytes directed against tumor antigen-MZ2-E. J. Exp. Med., 176: 1453-1457, 1992.
84. Boel, P., Wildmann, C., and Sensi, M. L. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity, 2: 167-175, 1995.
85. Coulie, P. G., Lehmann, F., and Lethe, B. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA, 92: 7976-7980, 1995.
86. Fisk, B., Blevins, T. L., and Wharton, J. T. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes lines. J. Exp. Med., 181: 2109-2117, 1995.
87. Linehan, D. C., Goedegebuure, P. S., and Peoples, G. E. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J. Immunol., 155: 4486-4491, 1995.
88. Ressing, M. E., Van Driel, W., and Cells, E. Occasional memory CTL responses of patients with human papillomavirus type 16 positive cervical lesions against a human leukocyte antigen A*0201 restricted E7 encoded epitope. Cancer Res., 56: 582-588, 1996.
89. Tsang, K. Y., Zaremba, S., and Nieroda, C. A. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccina-CEA vaccine. J. Natl. Cancer Inst, 87: 982-990, 1995.
90. Disis, M. L., Calenoff, E., and McLaughlin, G. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res., 54: 16-20, 1994.
91. Disis, N. L., Gralow, J. R., and Bernhard, H. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J. Immunol., 156: 3151-3158, 1996.
92. Kast, W. M., Brandt, R. P. M., and Sidney, J. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol., 152: 3904-3912, 1994.
93. Feltkamp, M. C. W., Smits, H. L., and Vierboom, M. P. M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol., 23: 2242-2249, 1993.
94. Kubo, R. T., Sett, A., and Grey, H. M. Definition of specific peptide motifs for four major HLA-A alleles. J. Immunol., 752: 3913-3924, 1994.
95. Vitiello, A., Ishioka, G., and Grey, H. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J. Clin. Invest., 95: 341-349, 1995.
96. Mayordomo, J. L., Zorina, T., and Storkus, W. J. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1: 1297-1302, 1995.
97. Young, J. W., and Inaba, K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med., 183: 7-11, 1996.
98. Zitvogel, L., Mayordomo, J. I., and Tjandrawan, T. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cell, B7 co-stimulation, and T helper cell 1-associated cytokines. J. Exp. Med., 183: 87-97, 1996.
99. Porgador, A., Snyder, D., and Gilboa, E. Induction of antitumor immunity using bone-marrow generated dendritic cells. J. Immunol., 156: 2918-2926, 1996.
100. Marchand, M., Weynants, P., and Rankin, E. Tumor regression responses in melanoma patients treated with a peptide encoded by the gene MAGE-3. Int. J. Cancer, 63: 883-885, 1995.
101. Parkhurst, M. R., Salgaller, M. L., and Southwood, S. Improved induction of melanoma reactive CTL with peptides from melanoma antigen gp100 modified at HLA-A*0201 binding residues. J. Immunol., 157: 2539-2548, 1995.
102. Mukherji, B., Chakrababorty, N. G., and Yamasaki, S. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen-presenting cells. Proc. Natl. Acad. Sci. USA, 92: 8078-8082, 1995.
103. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-332, 1998.
104. Kotera, Y., Fontenot, J. D., Pecher, G., Metzgar, R. S., and Finn, O. J. Human immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res., 54: 2856-2860, 1994.
105. Devine, P. L., Layton, G. T., Clark, B. A., Birrell, G. W., Ward, B. G., Xing, P. X., and McKenzie, F. C. Production of MUC1 and MUC2 mucins by human tumor cell lines. Biochem. Biophys. Res. Commun., 178: 593-599, 1991.
106. Hollingsworth, M. A., Strawhecker, J. M., Caffrey, T. C., and Mack, D. R. Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines. Int. J. Cancer, 57: 198-203, 1994.
107. Hareuveni, M., Gautier, C., Kieny, M-P., Wreschner, D., Chambon, P., and Lathe, R. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc. Natl. Acad. Sci. USA, 87: 9498-9502, 1990.
108. Gendler, S. J., Spicer, A. P., Lalani E-N., Duhig, T., Peat, N., Burchell, J., Pemberton, L., Boshell, M., and Taylor-Papadimitriou, J. Structure and biology of a carcinoma-associated mucin, MUC1. Am. Rev. Respir. Dis., 144: S42-S47, 1991.
109. Burchell, J., Taylor-Papadimitriou, J., Boshell, M., Gendler, S., and Duhig, T. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int. J. Cancer, 44: 691-696, 1989.
110. Fontenot, J. D., Tjandra, N., Bu, D., Ho, C, Montelaro, R. C., and Finn, O. J. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res., 53: 5386-5394, 1993.
111. Perez, L., Hayes, D. F., Maimonis, P., Abe, M., O'Hara, C., and Kufe, D. W. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res., 52: 2563-2568, 1992.
112. Ding, L., Lalani, E-N., Reddish, M., Koganty, R., Wong, T., Samuel. J., Yacyshyn, M. B., Meikle, A., Fung, P. Y. S., Taylor-Papadimitriou, J., and Longenecker, B. M. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother., 36: 9-17, 1993.
113. Barnd, D. L., Lan, M., Metzgar, R., and Finn, O. J. Specific MHC-unrestricted recognition of tumor associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA, 86: 7159-7163, 1989.
114. Jerome, K. R., Barnd, D. L., and Bendt, K. M. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res., 51: 2908-2916, 1991.
115. Goydos, J. S., Elder, E., Whiteside, T. L., Finn, O. J., and Lotze, M. T. A phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res., 63: 298-304, 1996.
116. Doménech, N., Henderson, R. A., and Finn, O. J. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol., 155: 4766-4774, 1995.
117. Apostolopoulos, V., Osinski, C., and McKenzie, I. F. C. MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat. Med., 4: 315-320, 1998.
118. Houghton, A. N., and Lloyd, K. O. Stuck in the MUC on the long and winding road: antibodies that cross react with the tumor antigen MUC1 switch a cellular immune response to a humoral one with implications for the immunotherapy of cancer. Nat. Med., 4: 270-271, 1998.
119. Livingston, P. O., Ritter, F., Srivastava, P., Padavan, M., Calves, M. J., Oettgen, H. F., and Old, L. J. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res., 49: 7045-7050, 1984.
120. Livingston, P. O., Natoli, E. J., Jr., Calves, M. J., Stockert, E., Oettgen, H. F., and Old, L. J. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. USA, 84: 2911-2915, 1987.
121. Livingston, P. O., Wong, G. Y. C., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hamlon, G., Calves, M. J., Helling, F., Ritter, G., Oettgen, H. F., and Old. L. J. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol., 12: 1036-1044, 1994.
122. Sieling, P. A., Chatterjee. D., Porcelli, S. A., Prigozy, T. I., Mazzaccaro, R. J., Soriano, T., Bloom, B. R., Brenner, M. B., Kronenberg, M., Brennan, P. J., et al. CD1-restricted T-cell recognition of microbial lipoglycan antigens. Science (Washington DC), 269: 227-230, 1985.
123. Moody, D. B., Reinhold, B. B., Guy, M. R., Beckman, E. M., Frederique, D. E., Furlong, S. T., Ye, S., Reinhold, V. N., Sieling, P. A., Modlin, R. L., Besra, G. S., and Porcelli, S. A. Structural requirements for glycolipid antigen recognition by CD1b-restricted T-cells. Science (Washington DC), 278: 283-286, 1997.
124. Haurum, J. S., Arsequell, G., Lellouch, A. C., Wong, S. Y. C., Dwek, R. A., McMichael, A. J., and Elliot, T. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J. Exp. Med., 180: 739-744, 1994.
125. + T cells. Nature (Lond.), 372: 691-694, 1994.
126. Springer, G. F. T and Tn, general carcinoma antoantigens. Science (Washington DC), 224: 1198-1206, 1984.
127. Longenecker, B. M., Willan, D. J., and MacLean, G. D. Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers. J. Natl. Cancer Inst., 78: 489-496, 1987.
128. Samuel, J., Noujaim, A. A., and MacLean, G. D. Analysis of human tumor associated Thomsen-Friedenreich antigen. Cancer Res, 50: 4801-4808, 1990.
129. Springer, G. F., Taylor, C. R., and Howard, D. R. Tn. a carcinoma associated antigen, reacts with anti-Tn of normal human sera. Cancer (Phila.), 55: 561-569, 1985.
130. Itzkowitz, S. H., Bloom, E. J., and Kokal, W. A. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer (Phila.), 66: 1960-1966, 1990.
131. Itzkowitz, S., Yuan, M., and Montgomery, C. K. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res., 49: 197-204, 1989.
132. MacLean, G. D., Reddish, M. A., Bowen-Yacshyn, M. B., Poppema, S., and Longenecker, B. M. Active specific immunotherapy against adenocarcinomas. Cancer Investig., 12: 46-56, 1994.
133. Adluri, S., Helling, F., Ogata, S., Zhang, S., Itzkowitz, S. H., Lloyd, K. O., and Livingston, P. O. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol. Immunother., 41: 185-192, 1995.
134. Thompson, J., and Zimmerman, W. The carcinoembryonic antigen gene family: structure, expressions, and evolution. Tumour Biol., 9: 63-83, 1988.
135. Paxton, R. J., Mooser, G., Pande, H., Lee, T. D., and Shivley, J. E. Sequence analysis of carcinoembryonic antigen: identification of glycosylation sites and homology with the immunoglobulin super-gene family. Proc. Natl. Acad. Sci. USA, 84: 920-924, 1987.
136. Benchimol, S., Fuks, A., Jothy, S., Beauchemia, N., Shirota, K., and Stanners, C. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell, 57: 327-334, 1989.
137. Oikawa, S., Inuzuka, C., Kuroki, M., Matsuoka, Y., Kosaki, G., and Nakazato, H. Cell adhesion activity of non-specific cross-reacting antigen (NCA) and carcinoembryonic antigen (CEA) expressed on CHO cell surface: homophilic and heterophilic adhesion. Biochem. Biophys. Res. Commun., 164: 39-45, 1989.
138. Kaufman, H., Schlom, J., and Kantor, J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int. J. Cancer, 48: 900-907, 1991.
139. Kantor, J., Irvine, K., Abrams, S., Kaufman, H., DiPietro, J., and Schlom, J. Antitumor activity and immune response induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst., 84: 1084-1091, 1992.
140. Kantor, J., Irvine, K., Abrams, S., Snoy, P., Olsen, R., Greiner, J., Kaufman, H., Eggensperger, D., and Schlom, J. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res., 52: 6917-6925, 1992.
141. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., and Schlom, J. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen (CEA) epitopes from patients immunized with recombinant vaccinia-CEA (rV-CEA) vaccine. J. Natl. Cancer Inst., 87: 982-990, 1995.
142. McLaughlin, J. P., Schlom, J., Kantor, J. A., and Greiner, J. W. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res., 56: 2361-2367, 1996.
143. Conry, R. M., LoBuglio, A. F., Kantor, J., Schlom, J., Loechel, F., Moore, S. E., Sumerel, L. A., Barlow, D. L., Abrams, S., and Curiel, D. T. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res., 54: 1164-1168, 1994.
144. Lindenmann, J. Speculations on idiotypes and homebodies. Ann. Immunol. (Paris), 124: 171-184, 1973.
145. Jerne, N. K. Towards a network theory of the immune system. Ann. Immunol. (Paris), 125C: 373-389, 1974.
146. Fagerberg, J., Steinitz, M., Wigzell, H., Askelöf, P., and Mellstedt, H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc. Natl. Acad. Sci. USA, 92: 4773-4777, 1995.
147. Herlyn, D., Harris, D., Zaloudik, J., Sperlagh, M., Maruyama, H., Jacob, L., Kieny, M-P., Scheck, S., Somasundaram, R., Hart, E., Ertl, H., and Mastrangelo, M. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients. J. Immunother., 15: 303-311, 1994.
148. Robins, R. A., Denton, G. W. L., Hardcastle, J. D., Austin, E. B., Baldwin, R. W., and Durrant, L. G. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res., 51: 5425-5429, 1991.
149. Denton, G. W. L., Durrant, L. G., Hardcastle, J. D., Austin, E. B., Sewell, H. F., and Robins, R. A. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int. J. Cancer, 57: 10-17, 1994.
150. Durrant, L. G., Buckley, T. J. D., Denton, G. W. L., Hardcastle, J. D., Sewell, H. F., and Robins, R. A. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res., 54: 4837-4840, 1994.
151. Durrant, L. G., Doran, M., Austin, E. B., and Robins, R. A. Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumours. Int. J. Cancer, 61: 62-66, 1995.
152. Bhattacharya-Chatterjee, M., Mukerjee, S., Biddle, W., Foon, K. A., and Köhler, H. Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J. Immunol., 145: 2758-2765, 1990.
153. Pervin, S., Chakraborty, M., Bbattacbarya-Chatterjee, M., Zeytin, H., Foon, K. A., and Chatterjee, S. Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res., 57: 728-734, 1997.
154. Foon, K. A., Chakraborty, M., John, W. J., Sherratt, A., Köhler, H., and Bhattacharya-Chatterjee, M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J. Clin. Invest., 96: 334-342, 1995.
155. Foon, K. A., John, W. J., Chakraborty, M., Sherratt, A., Garrison, J., Flett, M., and Bhattacharya-Chatterjee, M. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin. Cancer Res., 3: 1267-1276. 1997.
156. Foon, K. A., John, W. J., Chakraborty, M., Garrison, J., Bard, V., and Bhattacharya-Chatterjee, M. Clinical and immune responses in surgically resected colorectal cancer (CRC) patients treated with an anti-idiotype (Id) monoclonal antibody that mimics carcinoembryonic antigen (CEA) with or without 5-fluorouracil. Proc. Am. Soc. Clin. Oncol., 17: 435a, 1998.
157. Chatterjee, S. K., Tripathi, P. K., Chakraborty, M., Yannelli, J., Wang, H., Foon, K. A., Maier, C. C., Blalock, E. J., and Bhattacharya-Chatterjee, M. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. Cancer Res., 58: 1217-1224, 1998.
158. Magliani, W., Polonelli, L., Conti, S., Salati, A., Rocca, P. F., Cusumano, V., Mancuso, G., Teti, G., et al. Neonatal mouse immunity against group B streptococcal infection by maternal vaccination with recombinant anti-idiotypes. Nat. Med., 4: 705-709, 1998.
159. Ruiz, P. J., Wolkowicz, R., Waisman, A., Hirschberg, D. L., Carmi, P., Erez, N., Garren, H., Herkel, J., Karpuj, M., Steinman, L., Rotter V, and Cohen, I. R. Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat. Med. 4: 710-712, 1998.
160. Bona, C. A. Idiotype vaccines: forgotten but not gone. Nat. Med., 4: 668-669, 1998.
161. Foon, K. A., and Bhattacharya-Chatterjee, M. Idiotype vaccines in the clinic. Nat. Med., 4: 870, 1998.
162. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Paton, V., Shak, S., Lieberman, G., and Slamon, D. Efficacy and safety of Herceptin™ (Humanized Anti-Her2 Antibody) as a single agent in 222 women with Her2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Am. Soc. Clin. Oncol., 17: 97a, 1998.
163. Slamon, D., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Baselga, J., and Norton, L. Addition of Herceptin™ (Humanized Anti-Her2 Antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer (Her2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Am. Soc. Clin. Oncol., 17: 98a, 1998.